Amarin Corp Plc (AMRN)

[sts66]

The question of whether new trials and FDA approval for new indications can push patent protection out past 2029 has been a topic of debate here for several years, and nobody could answer the question - but a week or two ago, somebody did some research and discovered at least two drugs that got protection extended past original patent expiration by filing for a new indication - don't recall who posted it, but I know I responded to it as an "Aha!" moment - if you can search my posts, or figure out the keywords to use in a google search, you might find that thread. The question of what happens with Teva in 2029 if we get a new indication is still an unknown - AMRN made a deal, and they might have make a new one with Teva to tear up the old one, and it won't be cheap next time. Can't allow Teva to enter the market for the CVD indication and stop them from gaining patients for the new indication, because you can't prevent docs from prescribing GV off label for the new one.